Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Iovance Biotherapeutics Q2 EPS $(0.33) Misses $(0.29) Estimate, Sales $59.952M Miss $69.792M Estimate

Author: Benzinga Newsdesk | August 07, 2025 03:03pm
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.29) by 14.58 percent. This is a 2.94 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $59.952 million which missed the analyst consensus estimate of $69.792 million by 14.10 percent. This is a 92.73 percent increase over sales of $31.106 million the same period last year.

Posted In: IOVA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist